Literature DB >> 18288212

Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.

A Hiasa1, M Hirayama, H Nishikawa, S Kitano, I Nukaya, S S Yu, J Mineno, I Kato, H Shiku.   

Abstract

In adoptive T-cell transfer as an intervention for malignant diseases, retroviral transfer of T-cell receptor (TCR) genes derived from CD8(+) cytotoxic T-lymphocyte (CTL) clones provides an opportunity to generate a large number of T cells with the same antigen specificity. We cloned the TCR-alphabeta genes from a human leukocyte antigen (HLA)-A(*)2402-restricted CTL clone specific for MAGE-A4(143-151). The TCR-alphabeta genes were transduced to 99.2% of non-TCR expressing SupT1, a human T-cell line, and to 12.7-32.6% of polyclonally activated CD8(+) T cells by retroviral transduction. As expected, TCR-alphabeta gene-modified CD8(+) T cells showed cytotoxic activity and interferon-gamma production in response to peptide-loaded T2-A(*)2402 and tumor cell lines expressing both MAGE-A4 and HLA-A(*)2402. A total of 24 clones were established from TCR-alphabeta gene-transduced peripheral blood mononuclear cells and all clones were functional on a transduced TCR-dependent manner. Four clones were kept in culture over 6 months for analyses in detail. The transduced TCR-alphabeta genes were stably maintained phenotypically, functionally and genetically. Our results indicate that TCR-transduced alphabeta T cells by retroviral transduction represent an efficient and promising strategy for adoptive T-cell transfer for long term.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288212     DOI: 10.1038/sj.gt.3303099

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.

Authors:  Takeshi Hanagiri; Yoshiki Shigematsu; Koji Kuroda; Tetsuro Baba; Hironobu Shiota; Yoshinobu Ichiki; Yoshika Nagata; Manabu Yasuda; Tomoko So; Mitsuhiro Takenoyama; Fumihiro Tanaka
Journal:  Cancer Sci       Date:  2012-07-06       Impact factor: 6.716

Review 2.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 3.  Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.

Authors:  Toshiki Ochi; Hiroshi Fujiwara; Masaki Yasukawa
Journal:  J Biomed Biotechnol       Date:  2010-05-05

4.  TCRγ4δ1-engineered αβT cells exhibit effective antitumor activity.

Authors:  Kangxia He; Hongqin You; Yuxia Li; Lianxian Cui; Jianmin Zhang; Wei He
Journal:  Mol Med       Date:  2016-07-26       Impact factor: 6.354

Review 5.  T-cell receptor gene therapy--ready to go viral?

Authors:  Terhi Karpanen; Johanna Olweus
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

6.  A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression.

Authors:  Sachiko Okamoto; Yasunori Amaishi; Yumi Goto; Hiroaki Ikeda; Hiroshi Fujiwara; Kiyotaka Kuzushima; Masaki Yasukawa; Hiroshi Shiku; Junichi Mineno
Journal:  Mol Ther Nucleic Acids       Date:  2012-12-18       Impact factor: 10.183

Review 7.  Clinical application of adoptive T cell therapy in solid tumors.

Authors:  Yi-Wen Zang; Xiao-Dong Gu; Jian-Bin Xiang; Zong-You Chen
Journal:  Med Sci Monit       Date:  2014-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.